AEON Biopharma, Inc.
AEONNYSE
$0.29
↓ -0.8%Jul 17 close · end-of-day
Price
1Y↓ -61.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$12.0M
Enterprise Value
$5.7M
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$60.1M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
358.8%
ROIC
—
Debt / Equity
—
Net Cash
$6.2M
Return 1Y
-62.1%
Company profile
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine. AEON Biopharma, Inc. is based in Irvine, California.
- CEO
- Marc Forth
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- California
- Website
- aeonbiopharma.com
Management & directors
- Bencich JohnCHIEF FINANCIAL OFFICER
- Oh ChadCHIEF MEDICAL OFFICER
- Sy JenniferPRINCIPAL ACCOUNTING OFFICER
- Wilson Alexander BlairCLO, CSO, and Corp Secretary
- Bancroft Robert E.PRESIDENT & CEO
Roles derived from SEC Form 4 filings.
Earnings
AEON Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.29↓ -112.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$1.9M | -$48.4M | $73.0M | -$12.8M |
| Net income | $8.2M | -$52.6M | $42.0M | -$39.2M |
| Diluted EPS | — | -$0.38 | $72.93 | -$3.95 |
| Operating cash flow | -$1.5M | -$35.6M | -$20.3M | -$17.3M |
| Free cash flow | — | -$35.9M | — | -$17.3M |
| Gross margin | — | — | — | — |
| Operating margin | — | — | — | — |
| Net margin | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $153.5M | -$4.0M | -$2.3M | -$462,000.00 | -$4.3M | -$2.5M | -$5.5M | -$5.9M |
| Net income | $164.1M | -$6.2M | $2.1M | $9.1M | -$6.6M | -$4.5M | -$37.1M | -$11.8M |
| Diluted EPS | $304.00 | -$11.24 | $8.04 | $2.28 | -$0.60 | -$0.39 | -$5.24 | -$0.29 |
| Operating cash flow | -$8.1M | -$3.0M | -$621,000.00 | -$7.9M | -$2.1M | -$2.6M | -$4.7M | -$2.6M |
| Free cash flow | — | — | — | -$7.9M | -$2.1M | -$2.6M | -$4.7M | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-17 | Thunen Shelley B | Award | 222,684 | $0.00 | $0.00 | filing |
| 2026-06-17 | PALMISANO ROBERT J | Award | 222,684 | $0.00 | $0.00 | filing |
| 2026-06-17 | Forth Marc | Award | 222,684 | $0.00 | $0.00 | filing |
| 2026-06-17 | FISCHER JOST | Award | 222,684 | $0.00 | $0.00 | filing |
| 2026-06-17 | Carter Eric G | Award | 222,684 | $0.00 | $0.00 | filing |
| 2026-04-02 | Bencich John· CHIEF FINANCIAL OFFICER | Award | 754,717 | $0.00 | $0.00 | filing |
| 2026-03-04 | Oh Chad· CHIEF MEDICAL OFFICER | Award | 1,316,872 | $0.00 | $0.00 | filing |
| 2026-03-04 | Wilson Alexander Blair· CLO, CSO, and Corp Secretary | Award | 1,316,872 | $0.00 | $0.00 | filing |
| 2026-03-04 | Sy Jennifer· PRINCIPAL ACCOUNTING OFFICER | Award | 925,925 | $0.00 | $0.00 | filing |
| 2026-02-17 | Oh Chad· CHIEF MEDICAL OFFICER | Award | 862,500 | $0.00 | $0.00 | filing |
| 2026-02-17 | Wilson Alexander Blair· CLO, CSO, and Corp Secretary | Award | 862,500 | $0.00 | $0.00 | filing |
| 2026-02-17 | Sy Jennifer· PRINCIPAL ACCOUNTING OFFICER | Award | 575,000 | $0.00 | $0.00 | filing |
| 2026-02-17 | Bancroft Robert E.· PRESIDENT & CEO | Award | 3,000,000 | $0.00 | $0.00 | filing |
Latest 13 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.